Sun, 28 Jun 2026 · LIVE
Updated Jun 28, 2026 · 18:35
Gujarat News Updated Jun 28, 2026

Gujarat Unveils $300 Billion Bio-Economy Roadmap by 2030

A new report by GRIT outlines Gujarat's ambition to become India's leading biotech hub by 2030. The state aims to leverage its 40% share of India's pharma production and strong chemical manufacturing base. Key growth drivers include biopharma, bio-industrial manufacturing, and bio-agriculture. The report emphasizes developing a skilled workforce through specialized education to support the $300 billion national bio-economy target.

Gujarat seeks to build biotechnology, biomanufacturing hub by 2030: Report

Gandhinagar, June 28

A new report by the Gujarat Rajya Institute for Transformation on Sunday outlined an ambitious roadmap for Gujarat to emerge as India's leading biotechnology and biomanufacturing hub by 2030, with a strong focus on developing a skilled workforce, extending specialised education and strengthening industry-oriented training.

The report, titled 'Gujarat Bio-Economy 2030: Strategic Skill Architecture and Workforce Development', said that India's bio-economy has rose from around $10 billion in 2014 to more than $150 billion in 2024.

Backed by the Centre's BioE3 Policy (Biotechnology for Economy, Environment and Employment), the country has set a target of building a $300 billion bio-economy by the end of the decade, with Gujarat expected to play a significant role.

According to the report, Gujarat is well positioned to support that target because it accounts for around 40 per cent of India's pharmaceutical production and is one of the country's leading chemical manufacturing centres.

"Under the leadership of Chief Minister Bhupendra Patel, the state aims to strengthen its position in biotechnology and biomanufacturing by leveraging its existing industrial base and expanding its skilled talent pool," an official said.

The report notes that the national bio-economy target is based on expected growth in both domestic demand and exports. It identifies biopharma, bio-industrial manufacturing and bio-agriculture as the principal drivers of future growth.

Biopharma, which contributes about 35 per cent of the sector, continues to be driven by vaccines, therapeutics and diagnostics.

India currently supplies more than 35 per cent of global vaccine demand, and the report says "advances in technologies such as mRNA and viral vectors are expected to expand this capability further".

The bio-industrial segment, accounting for 47 per cent of the sector, is witnessing growing demand for fermentation technology specialists due to increased use of bio-based chemicals and the country's ethanol blending programme, which achieved its 20 per cent target ahead of schedule.

Bio-agriculture represents around eight per cent of the sector.

The report says climate change is advancing the adoption of technologies such as CRISPR-based crops and bio-fertilisers, which are moving from research laboratories to agricultural fields.

The BioE3 Policy places particular emphasis on creating a skilled workforce for high-performance biomanufacturing.

According to the policy, the availability of appropriate talent and supporting infrastructure will allow the sector to maximise its production capacity.

The report also highlights Gujarat's existing strengths, including its manufacturing ecosystem, research institutions, progressive policy framework, 1,600-km coastline and diverse agricultural base.

It states that these factors provide a strong foundation for the state to become a major participant in the global bio-economy.

Referring to the Gujarat State Biotechnology Policy 2022-27, the report says the state intends to move beyond large-scale production of generic medicines and expand into the development of innovative biologics, reflecting a broader shift from conventional industrial manufacturing towards a knowledge-driven bio-economy.

The report identifies the development of a strong local talent ecosystem as one of the state's biggest opportunities.

"Investing in specialised education and skills training could reduce the migration of skilled professionals, lower the need for workforce retraining and support sustainable industrial growth," it said.

As part of its assessment, GRIT examined 23 institutions offering biotechnology and related programmes across Gujarat.

The study concludes that the state already has a strong educational foundation capable of producing quality biotechnology professionals, while also identifying opportunities to further align academic curricula with emerging industry requirements so that graduates are better prepared for future employment in the sector.

— IANS

Reader Comments

Vikram M

As someone working in bio-manufacturing, this is encouraging. The focus on skilled workforce development is key—we have talent but often lack industry-ready skills. If Gujarat aligns its curriculum with BioE3 needs, it could become a global hub. But execution matters more than reports. Let's see ground-level implementation!

Ananya R

Impressive vision—$300 billion bio-economy by 2030! The CRISP-based crops and bio-fertilisers part excites me, especially with climate change hitting our farmers hard. But I hope this doesn't become another top-down policy where ground-level reality gets ignored. Let's involve local communities and farmers in this journey. 🌱

Rahul R

Gujarat has the infrastructure but needs to attract more research funding. We lag behind Bengaluru and Hyderabad in biotech startups. A separate biotech innovation fund and easier patent filing processes could help. Also, why is bio-agriculture only 8%? That should be a priority given our agricultural base. Just my two paise.

Priya S

Finally! As a biotech student in Ahmedabad, I've seen many classmates move to Bangalore for jobs. If Gujarat creates good opportunities here with proper training centres, we can retain local talent. The 1,600-km coastline is a huge advantage for marine biotech too—hope that's part of the plan! 🇮🇳👍

James A

Interesting read from an international perspective. India's bio-economy growth is remarkable—$10B to $150B in 10 years. Gujarat's pharma infrastructure gives it an edge. But to compete globally, they'll need to

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Reader Voices

Leave a comment

Be kind. Add to the conversation. 0/50
Thank you — your comment has been submitted.
JS blocked